Dizal Pharmaceutical News

Dizhe Pharmaceutical (688192): Innovative small-molecule innovative drugs at the source, going global

gtjaNov 12 20:07

Digel Pharmaceutical-U (688192): Domestic doses of suvortinib exceeded expectations, follow the progress of overseas declarations

china international capital corporationNov 8 07:51

Dizhe Pharmaceutical (688016): Insist on investing in R&D and commercialization of innovative drugs is imminent

sealand securitiesNov 8 00:00

Dizhe Pharmaceutical (688192): Revenue is in line with expectations, R&D pipeline progresses rapidly

huaxi securitiesNov 1 00:00

Dizhe Pharmaceutical (688192): The product is progressing smoothly

caitong securitiesSep 2 00:00

Digel Pharmaceuticals (688192): Continued release of suvortinib progresses rapidly with the rest of the pipeline

sealand securitiesAug 31 00:00

Digel Pharmaceutical (688192): Strong growth in sales revenue, obvious narrowing of losses

Aug 30 00:00

Dizhe Pharmaceutical (688192) In-depth Report: Leading Domestic Small Molecule Innovative Drug Company

sealand securitiesJun 20 20:36

Dizhe Pharmaceutical (688192): A globally based differentiated innovative pharmaceutical company

May 20 00:00

Dizhe Pharmaceutical (688192): The first year of commercialization has begun

caitong securitiesMay 14 00:00

Digel Pharmaceuticals (688192): Fast dosage of suvortinib is optimistic about innovative catalysis

May 6 00:00

Dizhe Pharmaceutical (688192): Revenue is in line with expectations, core products are progressing in an orderly manner worldwide

May 1 13:21

Dizhe Pharmaceutical (688192): Optimistic about global innovation from a high starting point

Mar 27 00:00

Digel Pharmaceuticals (688192): Outstanding commercialization performance of shuvertinib, excellent first-line treatment data

Nov 4, 2023 00:00

Digel Pharmaceutical-U (688192): Strong sales after Schwogel's launch and global clinical progress smoothly

Oct 31, 2023 12:56

Digger Pharmaceuticals (688192): Shuvortinib sales set sail, global differentiated pipeline continues to advance

Oct 30, 2023 14:07

Dietzer Pharmaceutical-U (688192): Shuvertinib approved for marketing, multiple registrations, clinical progress is worth looking forward to

中信證券Sep 4, 2023 00:00

Diezer Pharmaceutical-U (688192): Shuvertinib was approved for marketing, and the first batch of prescriptions was implemented and the research pipeline is progressing smoothly

中金公司Aug 31, 2023 00:00

Digger Pharmaceutical-U (688192): Committed to differentiated competition, is about to enter the commercialization stage

財通證券Jul 26, 2023 15:02

Digger Pharmaceuticals (688192): Source Innovation Is Gradually Entering a Harvest Period, Global Commercialization Accelerates Implementation

天風證券May 20, 2023 00:00